FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116780500> ?p ?o ?g. }

• W2116780500 endingPage "1854" @default.
• W2116780500 startingPage "1845" @default.
• W2116780500 abstract "Dose-dense chemotherapy has become a mainstay regimen in the adjuvant setting for women with high-risk breast cancer. We performed a systematic review and meta-analysis of the existing data from randomized controlled trials regarding the efficacy and toxicity of the dose-dense chemotherapy approach in nonmetastatic breast cancer. Randomized controlled trials that compared a dose-dense chemotherapy protocol with a standard chemotherapy schedule in the neoadjuvant or adjuvant setting in adult women older than 18 years with breast cancer were identified by searching The Cochrane Cancer Network register of trials, The Cochrane Library, and LILACS and MEDLINE databases (from January 1966 to January 2010). Hazard ratios (HRs) of death and recurrence and relative risks of adverse events were estimated and pooled. All statistical tests were two-sided. Ten trials met the inclusion criteria and were classified into two categories based on trial methodology. Three trials enrolling 3337 patients compared dose-dense chemotherapy with a conventional chemotherapy schedule (similar agents). Patients who received dose-dense chemotherapy had better overall survival (HR of death = 0.84, 95% confidence interval [CI] = 0.72 to 0.98, P = .03) and better disease-free survival (HR of recurrence or death = 0.83, 95% CI = 0.73 to 0.94, P = .005) than those on the conventional schedule. No benefit was observed in patients with hormone receptor–positive tumors. Seven trials enrolling 8652 patients compared dose-dense chemotherapy with regimens that use standard intervals but with different agents and/or dosages in the treatment arms. Similar results were obtained for these trials with respect to overall survival (HR of death = 0.85, 95% CI = 0.75 to 0.96, P = .01) and disease-free survival (HR of recurrence or death = 0.81, 95% CI = 0.73 to 0.88, P < .001). The rate of nonhematological adverse events was higher in the dose-dense chemotherapy arms than in the conventional chemotherapy arms. Dose-dense chemotherapy results in better overall and disease-free survival, particularly in women with hormone receptor–negative breast cancer. However, additional data from randomized controlled trials are needed before dose-dense chemotherapy can be considered as the standard of care." @default.
• W2116780500 created "2016-06-24" @default.
• W2116780500 creator A5007458418 @default.
• W2116780500 creator A5012814827 @default.
• W2116780500 creator A5014435335 @default.
• W2116780500 creator A5035946224 @default.
• W2116780500 creator A5049406914 @default.
• W2116780500 creator A5059876271 @default.
• W2116780500 date "2010-11-23" @default.
• W2116780500 modified "2023-10-16" @default.
• W2116780500 title "Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials" @default.
• W2116780500 cites W1905895680 @default.
• W2116780500 cites W1909650807 @default.
• W2116780500 cites W1946819517 @default.
• W2116780500 cites W1961026612 @default.
• W2116780500 cites W1964435302 @default.
• W2116780500 cites W1967089098 @default.
• W2116780500 cites W2009189135 @default.
• W2116780500 cites W2027906728 @default.
• W2116780500 cites W2075642745 @default.
• W2116780500 cites W2099562503 @default.
• W2116780500 cites W2101760255 @default.
• W2116780500 cites W2107328434 @default.
• W2116780500 cites W2111666200 @default.
• W2116780500 cites W2112217271 @default.
• W2116780500 cites W2136300726 @default.
• W2116780500 cites W2138877053 @default.
• W2116780500 cites W2140654333 @default.
• W2116780500 cites W2154864146 @default.
• W2116780500 cites W2157823046 @default.
• W2116780500 cites W2164409215 @default.
• W2116780500 doi "https://doi.org/10.1093/jnci/djq409" @default.
• W2116780500 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3001963" @default.
• W2116780500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21098761" @default.
• W2116780500 hasPublicationYear "2010" @default.
• W2116780500 type Work @default.
• W2116780500 sameAs 2116780500 @default.
• W2116780500 citedByCount "187" @default.
• W2116780500 countsByYear W21167805002012 @default.
• W2116780500 countsByYear W21167805002013 @default.
• W2116780500 countsByYear W21167805002014 @default.
• W2116780500 countsByYear W21167805002015 @default.
• W2116780500 countsByYear W21167805002016 @default.
• W2116780500 countsByYear W21167805002017 @default.
• W2116780500 countsByYear W21167805002018 @default.
• W2116780500 countsByYear W21167805002019 @default.
• W2116780500 countsByYear W21167805002020 @default.
• W2116780500 countsByYear W21167805002021 @default.
• W2116780500 countsByYear W21167805002022 @default.
• W2116780500 countsByYear W21167805002023 @default.
• W2116780500 crossrefType "journal-article" @default.
• W2116780500 hasAuthorship W2116780500A5007458418 @default.
• W2116780500 hasAuthorship W2116780500A5012814827 @default.
• W2116780500 hasAuthorship W2116780500A5014435335 @default.
• W2116780500 hasAuthorship W2116780500A5035946224 @default.
• W2116780500 hasAuthorship W2116780500A5049406914 @default.
• W2116780500 hasAuthorship W2116780500A5059876271 @default.
• W2116780500 hasBestOaLocation W21167805001 @default.
• W2116780500 hasConcept C121608353 @default.
• W2116780500 hasConcept C126322002 @default.
• W2116780500 hasConcept C141071460 @default.
• W2116780500 hasConcept C143998085 @default.
• W2116780500 hasConcept C168563851 @default.
• W2116780500 hasConcept C197934379 @default.
• W2116780500 hasConcept C207103383 @default.
• W2116780500 hasConcept C2776478404 @default.
• W2116780500 hasConcept C2776694085 @default.
• W2116780500 hasConcept C2781413609 @default.
• W2116780500 hasConcept C44249647 @default.
• W2116780500 hasConcept C530470458 @default.
• W2116780500 hasConcept C71924100 @default.
• W2116780500 hasConcept C82789193 @default.
• W2116780500 hasConcept C95190672 @default.
• W2116780500 hasConceptScore W2116780500C121608353 @default.
• W2116780500 hasConceptScore W2116780500C126322002 @default.
• W2116780500 hasConceptScore W2116780500C141071460 @default.
• W2116780500 hasConceptScore W2116780500C143998085 @default.
• W2116780500 hasConceptScore W2116780500C168563851 @default.
• W2116780500 hasConceptScore W2116780500C197934379 @default.
• W2116780500 hasConceptScore W2116780500C207103383 @default.
• W2116780500 hasConceptScore W2116780500C2776478404 @default.
• W2116780500 hasConceptScore W2116780500C2776694085 @default.
• W2116780500 hasConceptScore W2116780500C2781413609 @default.
• W2116780500 hasConceptScore W2116780500C44249647 @default.
• W2116780500 hasConceptScore W2116780500C530470458 @default.
• W2116780500 hasConceptScore W2116780500C71924100 @default.
• W2116780500 hasConceptScore W2116780500C82789193 @default.
• W2116780500 hasConceptScore W2116780500C95190672 @default.
• W2116780500 hasIssue "24" @default.
• W2116780500 hasLocation W21167805001 @default.
• W2116780500 hasLocation W21167805002 @default.
• W2116780500 hasLocation W21167805003 @default.
• W2116780500 hasLocation W21167805004 @default.
• W2116780500 hasOpenAccess W2116780500 @default.
• W2116780500 hasPrimaryLocation W21167805001 @default.
• W2116780500 hasRelatedWork W1885119863 @default.
• W2116780500 hasRelatedWork W1900595920 @default.
• W2116780500 hasRelatedWork W2039727033 @default.

• next